IN THE NEWS
Mayne Pharma Announces Strategic investment in US Facilities
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals. Mayne Pharma provides contract development and manufacturing services to more than 100 clients worldwide...
To improve patient access to life-enhancing prescription medications, Mayne Pharma offers a robust portfolio of branded and generic drugs in multiple therapeutic areas, including women's health, oncology, dermatology and cardiology.
NEWS AND EVENTS
FY18 Results Briefing Webcast to be held on Friday 24th August 2018 at 10.00am (AEST) Mayne Pharma Acquires Generic Efudex®, Complementing US Dermatology Portfolio Mayne Pharma further strengthens Board with New Director Mayne Pharma strengthens Board with new Director Mayne Pharma Announces FDA Acceptance of new Drug Application for its Antifungal Suba®-Itraconazole Capsule
One of the keys to Mayne Pharma’s success has been the implementation of strategic partnerships and alliances by licensing products that we are able to market in the USA or Australia and to develop partnerships for the global marketing of products developed by Mayne Pharma...
Mayne Pharma has a 30-year track record of innovation and success developing new oral drug delivery systems and these technologies have been successfully commercialized in numerous products that have been marketed around the world...
|Market Cap:||52 Week: -|